Irbesartan Plus Hct Hennig (Hydrochlorothiazide, Irbesartan)

• Irbesartan plus Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to control high blood pressure.
• Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
• Essential hypertension: provides consistent blood‑pressure control when monotherapy is insufficient.
• Diastolic hypertension: improves diastolic control while maintaining target systolic levels.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of water and electrolytes. The combined actions produce vasodilation and a reduction in circulating blood volume, resulting in lowered arterial pressure. These effects are additive and help achieve target blood pressure more effectively than either component alone.

Irbesartan plus Hydrochlorothiazide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Increased frequency of urination
• Electrolyte disturbances such as low potassium
• Mild fatigue
• Transient nausea

Serious or Rare Side Effects

• Severe dehydration
• Acute kidney injury
• Angioedema or severe hypotension
• Hyperkalemia
• Persistent severe hyponatremia

When prescribing Irbesartan Plus Hct Hennig, clinicians should consider several safety measures.

• Monitor blood pressure regularly: ensure therapeutic targets are met without excessive lowering.
• Assess renal function before initiation and periodically: adjust therapy if creatinine rises.
• Check serum electrolytes: watch for potassium and sodium abnormalities.
• Use with caution in elderly patients: increased sensitivity to volume depletion.
• Contraindicated in pregnancy: safety category unknown; avoid use.
• Store at room temperature: keep in the original pack, protect from moisture.

Irbesartan plus Hydrochlorothiazide can interact with other medicines; awareness of the interaction level guides management.

Major Interactions (Avoid)

• Aliskiren: combined use may increase risk of renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• ACE inhibitors: additive effects on potassium and renal function.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive response and affect renal function.
• Antidiabetic agents: blood‑glucose control may change; monitor glucose levels.